Crinetics Pharmaceuticals CRNX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Crinetics Pharmaceuticals (CRNX) Business Model and Operations Summary
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Key Insights
Crinetics Pharmaceuticals (CRNX) Core Market Data and Business Metrics
Latest Closing Price
$30.62Market Cap
$2.84 BillionPrice-Earnings Ratio
-8.25Total Outstanding Shares
93.05 Million SharesTotal Employees
437Dividend
No dividendIPO Date
July 18, 2018SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
10222 Barnes Canyon Road, Bldg. #2, San Diego, CA, 92121
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-120.04 Million |
| Net Cash Flow From Investing Activities, Continuing | $-120.04 Million |
| Net Cash Flow From Operating Activities | $-199.81 Million |
| Net Cash Flow From Operating Activities, Continuing | $-199.81 Million |
| Net Cash Flow From Financing Activities, Continuing | $494.32 Million |
| Net Cash Flow | $174.47 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Operating Expenses | $86.38 Million |
| Costs And Expenses | $299.73 Million |
| Research and Development | $219.17 Million |
| Operating Income/Loss | $-306.77 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Diluted Average Shares | $234.46 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-6.91 Million |
| Comprehensive Income/Loss Attributable To Parent | $-275.01 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-275.01 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $48.08 Million |
| Other Current Assets | $14.89 Million |
| Other Current Liabilities | $48.62 Million |
| Equity Attributable To Parent | $832.98 Million |
| Noncurrent Assets | $59.79 Million |
| Equity | $832.98 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||